Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2603332 | 1.00 | SLC18A3 (0.32) | SLC18A3CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL2603339 | 1.00 | SLC18A3 (0.32) | SLC18A3CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL2603338 | 1.00 | SLC18A3 (0.32) | SLC18A3CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL13910193 | 0.98 | SLC18A3 (0.35) | SLC18A3CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL11947594 | 0.98 | SLC18A3 (0.35) | SLC18A3CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL11947597 | 0.98 | SLC18A3 (0.35) | SLC18A3CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL17658848 | 0.95 | DPP7 (0.31) | L3MBTL1 | |
| SCHEMBL13910203 | 0.93 | SLC18A3 (0.35) | SLC18A3CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL21725587 | 0.93 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL10087580 | 0.91 | SLC18A3 (0.36) | SLC18A3CYP2D6MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075968-A1 | CETP inhibitors | SAKAKI JUNICHI | 2009-03-19 | — | — | US | disclosed |
| US-20090075968-A1 | CETP inhibitors | SAKAKI JUNICHI | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075968-A1 | CETP inhibitors | CETP, PCSK9, MTTP | SLC18A3 3320/4885CYP2D6 922/4885MEN1 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.